These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Starving the virus.
    Journal: Res Initiat Treat Action; 1999 Apr; 5(2):32-3. PubMed ID: 11366283.
    Abstract:
    The U.S. Food and Drug Administration approved clinical testing for an investigational new drug, HE2000. The drug, manufactured by Hollis-Eden Pharmaceuticals, blocks certain cellular enzymes and starves the virus of compounds necessary for replication. One advantage of HE2000 is that it targets cellular components instead of viral components, and therefore avoids the problem of the virus becoming drug resistant. Clinical trials are being conducted in four U.S. cities. Contact information is included.
    [Abstract] [Full Text] [Related] [New Search]